REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 174 filers reported holding REATA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $23,907,377 | +44.5% | 234,478 | +32.6% | 4.81% | +12.0% |
| Q1 2023 | $16,544,794 | +124.3% | 176,874 | -8.9% | 4.30% | +124.6% |
| Q4 2022 | $7,376,936 | +63.9% | 194,181 | +8.4% | 1.91% | +79.5% |
| Q3 2022 | $4,500,000 | -17.7% | 179,058 | -0.5% | 1.07% | -29.8% |
| Q2 2022 | $5,470,000 | -7.2% | 180,000 | 0.0% | 1.52% | -4.0% |
| Q1 2022 | $5,897,000 | – | 180,000 | – | 1.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $110,053,269 | 27.64% |
| Ghost Tree Capital, LLC | 500,000 | $18,995,000 | 8.11% |
| First Light Asset Management, LLC | 2,062,453 | $78,352,589 | 7.27% |
| Boxer Capital, LLC | 1,230,004 | $46,727,852 | 2.46% |
| Sofinnova Investments, Inc. | 992,029 | $37,687,182 | 2.24% |
| Tri Locum Partners LP | 141,466 | $5,374,000 | 2.17% |
| MPM BioImpact LLC | 194,181 | $7,376,936 | 1.91% |
| Ikarian Capital, LLC | 201,200 | $7,643,588 | 1.84% |
| KRS Capital Management, LLC | 28,141 | $1,069,077 | 1.46% |
| EMERALD ADVISERS, LLC | 679,772 | $25,824,538 | 1.25% |